[Bioforum] Molecular Therapy of Breast Cancer: Classicism Meets Modernity (book)

scimedweb via bioforum%40net.bio.net (by scimedweb from mail.com)
Sat Sep 5 05:51:28 EST 2009

NEW BOOK ! (September 2009)

Molecular Therapy of Breast Cancer: Classicism Meets Modernity
(by Marc Lacroix)

Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0

(hardcover): https://www.novapublishers.com/catalog/product_info.php?produc=
(online book): https://www.novapublishers.com/catalog/product_info.php?prod=

Breast cancer is the most frequently diagnosed type of cancer and a
second leading cause of cancer death in women after lung cancer.
Despite their proven efficacy, classical therapies are, however,
unable to cure metastatic breast cancer and are often associated with
significant toxicity and side-effects, due to a wide spectrum of
action. During the last years, our increasing knowledge of the
molecular pathways underlying cancer development has led to the
introduction of new drugs, of which most are directed towards very
specific targets. Rather than to be used as single agents, these
=93modern=94 compounds could ultimately be combined with =93classical=94

Here are described nearly 150 drugs that are currently (2009) used in
routine therapy or are in clinical trials in breast cancer patients.
>From the classical tamoxifen, fluorouracil, cyclophosphamide,
doxorubicin, epirubin, docetaxel, paclitaxel=85, to the more recently
introduced ixabepilone, lapatinib, vorinostat, everolimus,
bevacizumab=85, they also include capecitabine, gemcitabine,
trastuzumab, fulvestrant, aromatase inhibitors, cancer vaccines,
inhibitors of tumor-induced osteolysis, insulin-like growth factor-I
receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors,
and many others.

This book offers an insight into current developments of breast cancer
therapy, when classicism meets modernity.

Table of Contents:

Chapter 1. Introduction
Chapter 2. Selective estrogen receptor modulators (SERMs) and down-
regulators (SERDs)
Chapter 3. Aromatase inhibitors
Chapter 4. Agents inducing ovarian suppression
Chapter 5. Antimetabolites
Chapter 6. Alkylating agents
Chapter 7. Anthracyclines
Chapter 8. Microtubule-binding agents
Chapter 9. Topoisomerase inhibitors
Chapter 10. HER family inhibitors
Chapter 11. Angiogenesis inhibitors
Chapter 12. Insulin-like growth factor-I receptor inhibitors
Chapter 13. RAS-RAF-MEK-ERK pathway inhibitors
Chapter 14. Ubiquitin-proteasome system inhibitors
Chapter 15. Histone deacetylases inhibitors
Chapter 16. Mitotic inhibitors
Chapter 17. Inhibitors of heat-shock proteins 90 and 27
Chapter 18. PI3K/AKT/mTOR pathway inhibitors
Chapter 19. Cyclooxygenase-2 inhibitors
Chapter 20. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors
Chapter 21. Tumor-induced osteolysis inhibitors
Chapter 22. Vaccines and immunomodulators
Chapter 23. Varia

List of drugs/compounds discussed in the book:

ABT-888, ABT-869, Ad-sig-hMUC-1/ecdCD40L vaccine, AE37 peptide/GM-CSF
vaccine, Aflibercept, AFP464, AG014699, Alendronate, Aldesleukin,
Allogeneic GM-CSF-secreting breast cancer vaccine, ALT-801, AMG 386,
AMG 479, Anastrozole, Apricoxib, ARRY-334543, AS1402, ATN-224,
Autologous dendritic cell-adenovirus p53 vaccine, AV-951, AVE1642,
AVX701, AZD0530, AZD6244, Bavituximab, Belinostat, Bevacizumab,
BGT226, BIBW 2992, BMS-754807, Bortezomib, Bosutinib, BSI-201,
Busulfan, BZL101, Capecitabine, Carboplatin, CDX-1307, Celecoxib,
Cetuximab, CHP-HER2, CHP-NY-ESO-1, Cisplatin, Cixitumumab, Clodronate,
CNF2024, CR011-vcMMAE, Cyclophosphamide, Dasatinib, Deforolimus,
Denileukin diftitox, Denosumab, Docetaxel, Doxorubicin, Entinostat,
Enzastaurin, Epirubicin, Eribulin , Erlotinib, Ertumaxomab, Etoposide,
Everolimus, Exemestane, Falimarev, Figitumumab, Fluorouracil,
Fulvestrant, Gefitinib, Gemcitabine, Goserelin, GP2 peptide/GM-CSF
vaccine, GRN163L, GSK1059615, HER2/neu (extracellular domain) peptide
vaccine, hTERT/Survivin Multi-Peptide Vaccine, Ibandronate,
Ifosfamide, Imatinib, IMP321, Inalimarev, Interleukin-12, Irinotecan,
Ispinesib, Ixabepilone, Lapatinib, Larotaxel, Letrozole, Leuprolide,
Lonafarnib, Lonaprisan, Mammaglobin-A DNA vaccine, Melphalan,
Methotrexate, MK0646, MK-0752, MLN8237, Modified vaccinia Ankara
(Bavarian Nordic)-HER2 vaccine, Neratinib, NVP-AUY922, NVP-BEZ235,
Odanacatib, OGX-427, Olaparib, OSI-906, Ovarian Cancer Peptide Mix
Immunotherapeutic Vaccine, Oxaliplatin, Paclitaxel, Panobinostat,
Patupilone, Pazopanib, PD-0332991, Pemetrexed, Pertuzumab,Picoplatin,
pNGVL3-hICD vaccine, PTC299, Ramucirumab, Recombinant fowlpox-CEA(6D)/
TRICOM vaccine, Recombinant vaccinia-CEA(6D)-TRICOM vaccine,
Retaspimycin, Rexin-G, Risedronate, Sagopilone, SCH 727965, Sialyl
Lewis=AA-keyhole limpet hemocyanin (KLH) conjugate vaccine, Sirolimus,
Sorafenib, Sunitinib, Tamoxifen, Telomerase: 540-548 peptide vaccine,
Temozolomide, Temsirolimus, Tesmilifene, Thiotepa, Tipifarnib,
Toremifene, Trabectedin, Trastuzumab, Trastuzumab-MCC-DM1,
Triptorelin, TTK peptide (mixed with adjuvant Montanide ISA-51),
Valproic Acid, Vandetanib, Vinflunine, Vinorelbine, Vorinostat,
WX-671, Zoledronic Acid

More information about the Bioforum mailing list